Science
Eli Lilly's One-Shot Cholesterol Therapy Hits 88% PCSK9 Reduction in Phase 1, Gets Published in NEJM
VERVE-102, a base-editing treatment that inactivates the PCSK9 gene with a single infusion, showed durable LDL reductions of up to 62% in patients at high cardiovascular risk.
Science Desk